子宫内膜癌血清标志物的研究进展

Research progress of endometrial cancer serum marker

子宫内膜癌是常见的女性生殖道恶性肿瘤之一。近年来,受生活方式和环境等因素影响,子宫内膜癌的发病率逐渐上升。子宫内膜活体组织病理学检查是确诊子宫内膜癌的“金标准”,由于取样技术的侵入性在临床筛查的推广中受限。目前,临床最常检测的血清肿瘤标志物为糖类抗原125(CA125)和人附睾蛋白4(HE4),然而并非早期诊断的可靠工具。子宫内膜癌大部分是局限性病变,生存率相对较高,但常忽略早期不规则阴道流血和阴道排液等症状,尚缺乏有效的子宫内膜癌筛查手段,导致子宫内膜癌常常被延迟诊断,确诊时处于中晚期。因此寻求一种高特异性和高敏感性的无创性生物学指标来诊断早期子宫内膜癌显得至关重要。本文就无创性生物学指标在子宫内膜癌中的价值及其研究进展进行综述。

Endometrial carcinoma is one of the common female reproductive tract malignant tumor.In recent years,influenced by the factors such as lifestyle and environment,increase the incidence of endometrial cancer.Endometrial biopsy pathologic diagnosis of endometrial carcinoma is the"gold standard",as a result of the sampling technique of invasive limited in clinical screening for promotion.At present,clinical detection of serum tumor markers most often for carbohydrate antigen 125(CA125)and human epididymis protein 4(HE4),but not in early diagnosis of reliable tools.Endometrial cancer is mostly localized lesions,survival rates are relatively high,but often ignore the early symptoms such as irregular vaginal bleeding and vaginal drainage,and there is no effective means of endometrial cancer screening,lead to endometrial cancer is often delayed diagnosis,in the middle-late when confirmed.Therefore to seek a high specificity and sensitivity of noninvasive biological indicator crucial to early diagnosis of endometrial carcinoma.In this paper,the value of noninvasive biological indicator in endometrial carcinoma and its research progress were summarized.